Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVI NASDAQ:DCOY NASDAQ:FNCH NASDAQ:GRDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.38+5.3%$1.44$1.06▼$12.10$9.88M0.72108,238 shs59,018 shsDCOYDecoy Therapeutics$4.52-6.2%$6.43$4.52▼$415.80$2.56M0.3811,148 shs10,970 shsFNCHFinch Therapeutics Group$7.70+5.0%$9.27$2.00▼$16.10$12.37M1.185,025 shs13,507 shsGRDXEntero Therapeutics$3.64+5.5%$2.38$1.06▼$5.84$11.60M1.38112,434 shs288,996 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie+5.34%-10.39%-5.48%+8.66%-87.45%DCOYDecoy Therapeutics-6.22%-21.25%-27.10%-49.02%+451,999,900.00%FNCHFinch Therapeutics Group+5.05%-5.52%-3.75%-41.89%-41.00%GRDXEntero Therapeutics+5.51%+27.72%+76.70%+18.95%+363,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.38+5.3%$1.44$1.06▼$12.10$9.88M0.72108,238 shs59,018 shsDCOYDecoy Therapeutics$4.52-6.2%$6.43$4.52▼$415.80$2.56M0.3811,148 shs10,970 shsFNCHFinch Therapeutics Group$7.70+5.0%$9.27$2.00▼$16.10$12.37M1.185,025 shs13,507 shsGRDXEntero Therapeutics$3.64+5.5%$2.38$1.06▼$5.84$11.60M1.38112,434 shs288,996 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie+5.34%-10.39%-5.48%+8.66%-87.45%DCOYDecoy Therapeutics-6.22%-21.25%-27.10%-49.02%+451,999,900.00%FNCHFinch Therapeutics Group+5.05%-5.52%-3.75%-41.89%-41.00%GRDXEntero Therapeutics+5.51%+27.72%+76.70%+18.95%+363,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 1.00SellN/AN/ADCOYDecoy Therapeutics 2.00Hold$30.00563.72% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/AGRDXEntero Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DCOY, FNCH, GRDX, and BIVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/22/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/20/2026BIVIBioVie Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$2.07 per shareN/ADCOYDecoy TherapeuticsN/AN/AN/AN/A$7.29 per shareN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AGRDXEntero Therapeutics$36.25K337.58N/AN/A$7.42 per share0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$17.54M-$3.25N/AN/AN/AN/A-101.15%-90.18%N/ADCOYDecoy Therapeutics-$12.52M-$106.90N/AN/AN/AN/A-395.42%-193.30%N/AFNCHFinch Therapeutics Group-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/AGRDXEntero Therapeutics-$6.39M-$1.69N/AN/AN/AN/A-60.44%-7.05%N/ALatest DCOY, FNCH, GRDX, and BIVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q3 2026BIVIBioVie-$0.73-$0.70+$0.03-$0.70N/AN/A5/8/2026Q1 2026DCOYDecoy TherapeuticsN/A-$4.18N/A-$4.18N/AN/A5/1/2026Q4 2025GRDXEntero TherapeuticsN/A-$1.88N/A-$1.88N/AN/A3/31/2026Q4 2025DCOYDecoy TherapeuticsN/A$43.10N/A$43.10N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/ADCOYDecoy TherapeuticsN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AGRDXEntero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A9.967.25DCOYDecoy TherapeuticsN/A1.842.13FNCHFinch Therapeutics GroupN/A3.873.87GRDXEntero TherapeuticsN/A0.170.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%DCOYDecoy Therapeutics11.88%FNCHFinch Therapeutics Group21.77%GRDXEntero Therapeutics12.30%Insider OwnershipCompanyInsider OwnershipBIVIBioVie0.90%DCOYDecoy Therapeutics0.30%FNCHFinch Therapeutics Group44.90%GRDXEntero Therapeutics0.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie107.54 million7.47 millionNo DataDCOYDecoy Therapeutics20530,000530,000N/AFNCHFinch Therapeutics Group1901.61 million885,000No DataGRDXEntero Therapeutics93.36 million3.34 millionN/ADCOY, FNCH, GRDX, and BIVI HeadlinesRecent News About These CompaniesGridAI Technologies Corp. to Present at the Market Movers Investor SummitApril 29, 2026 | newsfilecorp.comNGridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K FilingApril 28, 2026 | newsfilecorp.comNGridAI Technologies Corp. Identifies Amp Z as Previously Announced Stealth Hyperscaler AI Data Center DeveloperMarch 4, 2026 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCOY, FNCH, GRDX, and BIVI Company DescriptionsBioVie NASDAQ:BIVI$1.38 +0.07 (+5.34%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.39 +0.01 (+1.01%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Decoy Therapeutics NASDAQ:DCOY$4.52 -0.30 (-6.22%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$4.53 +0.01 (+0.11%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.Finch Therapeutics Group NASDAQ:FNCH$7.70 +0.37 (+5.05%) As of 05/13/2026Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Entero Therapeutics NASDAQ:GRDX$3.64 +0.19 (+5.51%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$3.62 -0.02 (-0.55%) As of 05/14/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
